Innovent and Chi-Med evaluate combo in solid tumours

Sanofi & Alnylam conclude research & option phase of 2014 alliance
Credit: WAYHOME studio

China biopharma Innovent Biologics has forged a collaboration agreement with Hutchinson China MediTech (Chi-Med) to evaluable the combination of its Sintilimab and the latter’s fruquintinib in solid tumours.

The duo will jointly explore potential application of this combination in solid tumours with global unmet medical needs through development efforts both in the US and in China.

Dr Michael Yu, Founder, Chairman and CEO of Innovent, said: “There is strong scientific evidence supporting synergistic effects of PD-1 therapy when used in combination with VEGFR inhibitor.

“In addition, we hope to benefit from recent regulatory changes in China that allow for the recognition of foreign clinical trial data to possibly expedite the path to a China launch.”